Applied Genetic Technologies Corporation (AGTC)

NASDAQ: AGTC · IEX Real-Time Price · USD
0.286
+0.001 (0.35%)
Sep 27, 2022 3:21 PM EDT - Market closed
0.35%
Market Cap 19.11M
Revenue (ttm) 500,000
Net Income (ttm) -62.69M
Shares Out 66.81M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 654,555
Open 0.285
Previous Close 0.285
Day's Range 0.280 - 0.307
52-Week Range 0.280 - 3.295
Beta 1.26
Analysts Buy
Price Target 10.20 (+3,466.4%)
Earnings Date Nov 7, 2022

About AGTC

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has in... [Read more...]

Industry Biotechnology
IPO Date Mar 27, 2014
CEO Susan Washer
Employees 83
Stock Exchange NASDAQ
Ticker Symbol AGTC
Full Company Profile

Financial Performance

In 2021, AGTC's revenue was $500,000, a decrease of -79.62% compared to the previous year's $2.45 million. Losses were -$57.83 million, 26.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for AGTC stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 3,466.43% from the latest price.

Price Target
$10.2
(3,466.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AGTC to Participate in Upcoming Investor Conferences

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focu...

3 weeks ago - GlobeNewsWire

AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company's Design and Operating Procedures of its ...

— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC's pipeline, including the late-stage development and potential commercialization of AGTC's X-Linked Reti...

2 months ago - GlobeNewsWire

6 Penny Stocks With 1,000% Upside Potential

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance. The post 6 Penny Stocks With 1,000% Upside Potential appeared first on Inve...

Other symbols: ALZNAMPEBRDSCRISDRRX
2 months ago - InvestorPlace

AGTC Announces Pricing of $10 Million Underwritten Public Offering

GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focus...

2 months ago - GlobeNewsWire

AGTC Announces Proposed Underwritten Public Offering

GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focuse...

2 months ago - GlobeNewsWire

AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting

July 7, 2022 at 8:00 AM EDT July 7, 2022 at 8:00 AM EDT

2 months ago - GlobeNewsWire

Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer

SEATTLE, BOSTON & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Micha...

Other symbols: OCUL
3 months ago - Business Wire

AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of a...

3 months ago - GlobeNewsWire

AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Reti...

– 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study's Primary Efficacy Endpoint –

4 months ago - GlobeNewsWire

AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual M...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of ade...

4 months ago - GlobeNewsWire

AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Researc...

GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of ...

5 months ago - GlobeNewsWire

AGTC Announces Pricing of Public Offering of Common Stock

GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and...

6 months ago - GlobeNewsWire

AGTC Announces Proposed Public Offering of Common Stock

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and ...

6 months ago - GlobeNewsWire

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021

-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022-

7 months ago - GlobeNewsWire

AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and c...

7 months ago - GlobeNewsWire

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and c...

8 months ago - GlobeNewsWire

AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors

Robinson's expertise in development and commercialization adds to the clinical and commercial experience of newly appointed management team Robinson's expertise in development and commercialization adds...

9 months ago - GlobeNewsWire

AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-asso...

10 months ago - GlobeNewsWire

AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual...

- Poster presentation highlights safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) - - Poster presentation highlights safety and efficacy potential of AGT...

10 months ago - GlobeNewsWire

Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for...

10 months ago - Zacks Investment Research

AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021

-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022-

10 months ago - GlobeNewsWire

AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-asso...

10 months ago - GlobeNewsWire

AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-assoc...

11 months ago - GlobeNewsWire

AGTC Announces Two Key Leadership Team Appointments

- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sara...

11 months ago - GlobeNewsWire

AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-assoc...

11 months ago - GlobeNewsWire